Callegan, M. et al. Bacterial endophthalmitis: therapeutic challenges and host-pathogen interactions. Prog. Retin Eye Res. 26, 189–203 (2007).
Durand, M. L. Endophthalmitis. Clin. Microbiol. Infect. 19, 227–234 (2013).
Cioana, M. et al. Postintravitreal injection and postcataract extraction endophthalmitis visual outcomes by organism: a systematic review and meta-analysis. Retina 44, 1608–1618 (2024).
Al Mahmood, A. M., Al-Swailem, S. A. & Behrens, A. Clear corneal incision in cataract surgery. Middle East Afr. J. Ophthalmol. 21, 25–31 (2014).
Almanjoumi, A. M., Combey, A., Romanet, J. P. & Chiquet, C. 23-gauge transconjunctival sutureless vitrectomy in treatment of post-operative endophthalmitis. Graefes Arch. Clin. Exp. Ophthalmol. 250, 1367–1371 (2012).
Sadaka, A., Durand, M. L. & Gilmore, M. S. Bacterial endophthalmitis in the age of outpatient intravitreal therapies and cataract surgeries: host-microbe interactions in intraocular infection. Prog. Retin Eye Res. 31, 316–331 (2012).
Coburn, P. S. et al. Disarming pore-forming toxins with biomimetic nanosponges in intraocular infections. mSphere 4, e00262-19 (2019).
Miller, F. C. et al. Targets of immunomodulation in bacterial endophthalmitis. Prog. Retin Eye Res. 73, 100763 (2019).
Singh, S. et al. Integrative metabolomics and transcriptomics identifies itaconate as an adjunct therapy to treat ocular bacterial infection. Cell Rep. Med. 2, 100277 (2021).
Singh, S. et al. Myeloid cell-specific deletion of AMPKalpha1 worsens ocular bacterial infection by skewing macrophage phenotypes. J. Immunol. 213, 1656–1665 (2024).
Serhan, C. N., Chiang, N. & Van Dyke, T. E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8, 349–361 (2008).
Russell, C. D. & Schwarze, J. The role of pro-resolution lipid mediators in infectious disease. Immunology 141, 166–173 (2014).
Jordan, P. M. & Werz, O. Specialized pro-resolving mediators: biosynthesis and biological role in bacterial infections. FEBS J. 289, 4212–4227 (2022).
Yoo, S., Lim, J. Y. & Hwang, S. W. Resolvins: endogenously-generated potent painkilling substances and their therapeutic perspectives. Curr. Neuropharmacol. 11, 664–676 (2013).
Serhan, C. N. et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025–1037 (2002).
Serhan, C. N. et al. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J. Immunol. 176, 1848–1859 (2006).
Duvall, M. G. & Levy, B. D. DHA- and EPA-derived resolvins, protectins, and maresins in airway inflammation. Eur. J. Pharm. 785, 144–155 (2016).
Rajasagi, N. K., Reddy, P. B., Mulik, S., Gjorstrup, P. & Rouse, B. T. Neuroprotectin D1 reduces the severity of herpes simplex virus-induced corneal immunopathology. Investig. Ophthalmol. Vis. Sci. 54, 6269–6279 (2013).
Palmer, C. D. et al. 17(R)-Resolvin D1 differentially regulates TLR4-mediated responses of primary human macrophages to purified LPS and live E. coli. J. Leukoc. Biol. 90, 459–470 (2011).
Sulciner, M. L. et al. Resolvins suppress tumor growth and enhance cancer therapy. J. Exp. Med. 215, 115–140 (2018).
Ariel, A. et al. The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J. Biol. Chem. 280, 43079–43086 (2005).
Settimio, R., Clara, D. F., Franca, F., Francesca, S. & Michele, D. Resolvin D1 reduces the immunoinflammatory response of the rat eye following uveitis. Mediat. Inflamm. 2012, 318621 (2012).
Hsiao, H. M. et al. A novel anti-inflammatory and pro-resolving role for resolvin D1 in acute cigarette smoke-induced lung inflammation. PLoS ONE 8, e58258 (2013).
Mukherjee, P. K., Marcheselli, V. L., Serhan, C. N. & Bazan, N. G. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc. Natl. Acad. Sci. USA. 101, 8491–8496 (2004).
Gronert, K. et al. A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J. Biol. Chem. 280, 15267–15278 (2005).
Tang, Y. et al. Proresolution therapy for the treatment of delayed healing of diabetic wounds. Diabetes 62, 618–627 (2013).
Levy, B. D. et al. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J. Immunol. 178, 496–502 (2007).
Seki, H. et al. The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. J. Immunol. 184, 836–843 (2010).
El Kebir, D., Gjorstrup, P. & Filep, J. G. Resolvin E1 promotes phagocytosis-induced neutrophil apoptosis and accelerates resolution of pulmonary inflammation. Proc. Natl. Acad. Sci. USA. 109, 14983–14988 (2012).
Kurihara, T. et al. Resolvin D2 restores neutrophil directionality and improves survival after burns. FASEB J. 27, 2270–2281 (2013).
Orr, S. K. et al. Unesterified docosahexaenoic acid is protective in neuroinflammation. J. Neurochem. 127, 378–393 (2013).
Xu, Z. Z. et al. Neuroprotectin/protectin D1 protects against neuropathic pain in mice after nerve trauma. Ann. Neurol. 74, 490–495 (2013).
Serhan, C. N. et al. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J. Immunol. 171, 6856–6865 (2003).
Mustafa, M. et al. Resolvin D1 protects periodontal ligament. Am. J. Physiol. Cell Physiol. 305, C673–C679 (2013).
Morita, M. et al. The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell 153, 112–125 (2013).
Serhan, C. N., Krishnamoorthy, S., Recchiuti, A. & Chiang, N. Novel anti-inflammatory-pro-resolving mediators and their receptors. Curr. Top. Med. Chem. 11, 629–647 (2011).
Ahmad, Z. et al. Untargeted and temporal analysis of retinal lipidome in bacterial endophthalmitis. Prostaglandins Other Lipid Mediat. 171, 106806 (2024).
Zhang, Q. et al. Specialized pro-resolving lipid mediators: a key player in resolving inflammation in autoimmune diseases. Sci. Bull. 70, 778–794 (2025).
Kumar, A., Singh, P. K., Ahmed, Z., Singh, S. & Kumar, A. Essential role of NLRP3 inflammasome in mediating IL-1β production and the pathobiology of Staphylococcus aureus endophthalmitis. Infect. Immun. 90, e0010322 (2022).
Naik, P. et al. Multidrug-resistant Pseudomonas aeruginosa triggers differential inflammatory response in patients with endophthalmitis. Transl. Vis. Sci. Technol. 10, 26 (2021).
Kumar, A., Singh, C. N., Glybina, I. V., Mahmoud, T. H. & Yu, F. S. Toll-like receptor 2 ligand-induced protection against bacterial endophthalmitis. J. Infect. Dis. 201, 255–263 (2010).
Singh, P. K., Donovan, D. M. & Kumar, A. Intravitreal injection of the chimeric phage endolysin Ply187 protects mice from Staphylococcus aureus endophthalmitis. Antimicrob. Agents Chemother. 58, 4621–4629 (2014).
Das, S., Singh, S. & Kumar, A. Bacterial burden declines but neutrophil infiltration and ocular tissue damage persist in experimental Staphylococcus epidermidis endophthalmitis. Front. Cell. Infect. Microbiol. 11, 780648 (2021).
Talreja, D., Singh, P. K. & Kumar, A. In vivo role of TLR2 and MyD88 signaling in eliciting innate immune responses in staphylococcal endophthalmitis. Investig. Ophthalmol. Vis. Sci. 56, 1719–1732 (2015).
Poisson, L. M. et al. Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis. J. Biol. Chem. 290, 30697–30712 (2015).
Singh, P. K. & Kumar, A. Retinal photoreceptor expresses toll-like receptors (TLRs) and elicits innate responses following TLR ligand and bacterial challenge. PLoS ONE 10, e0119541 (2015).
Kochan, T., Singla, A., Tosi, J. & Kumar, A. Toll-like receptor 2 ligand pretreatment attenuates retinal microglial inflammatory response but enhances phagocytic activity toward Staphylococcus aureus. Infect. Immun. 80, 2076–2088 (2012).
Serhan, C. N. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92–101 (2014).
Zhang, H. et al. The common promoter polymorphism rs11666254 downregulates FPR2/ALX expression and increases risk of sepsis in patients with severe trauma. Crit. Care 21, 171 (2017).
Singh, P. K., Shiha, M. J. & Kumar, A. Antibacterial responses of retinal Muller glia: production of antimicrobial peptides, oxidative burst and phagocytosis. J. Neuroinflammation 11, 33 (2014).
Shamsuddin, N. & Kumar, A. TLR2 mediates the innate response of retinal Muller glia to Staphylococcus aureus. J. Immunol. 186, 7089–7097 (2011).
Singh, S., Singh, P. K. & Kumar, A. Butyrate ameliorates intraocular bacterial infection by promoting autophagy and attenuating the inflammatory response. Infect. Immun. 91, e0025222 (2023).
Francos-Quijorna, I. et al. Maresin 1 promotes inflammatory resolution, neuroprotection, and functional neurological recovery after spinal cord injury. J. Neurosci. 37, 11731–11743 (2017).
Kilburg-Basnyat, B. et al. Specialized pro-resolving lipid mediators regulate ozone-induced pulmonary and systemic inflammation. Toxicol Sci. 163, 466–477 (2018).
Fullerton, J. N., O’Brien, A. J. & Gilroy, D. W. Lipid mediators in immune dysfunction after severe inflammation. Trends Immunol. 35, 12–21 (2014).
Leslie, M. Inflammation’s stop signals. Science 347, 18–21 (2015).
Rossi, S. et al. Protection from endotoxic uveitis by intravitreal Resolvin D1: involvement of lymphocytes, miRNAs, ubiquitin-proteasome, and M1/M2 macrophages. Mediat. Inflamm. 2015, 149381 (2015).
Saban, D. R. et al. Resolvin D1 treatment on goblet cell mucin and immune responses in the chronic allergic eye disease (AED) model. Mucosal Immunol. 12, 145–153 (2019).
Gronert, K. Lipoxins in the eye and their role in wound healing. Prostaglandins Leukot. Ess. Fat. Acids 73, 221–229 (2005).
He, J. et al. Lipoxin A4 (LXA4) reduces alkali-induced corneal inflammation and neovascularization and upregulates a repair transcriptome. Biomolecules 13, 831 (2023).
Wei, J. et al. A novel role for lipoxin A(4) in driving a lymph node-eye axis that controls autoimmunity to the neuroretina. Elife 9, e51102 (2020).
Mursalin, M. H. et al. C-X-C chemokines influence intraocular inflammation during bacillus endophthalmitis. Investig. Ophthalmol. Vis. Sci. 62, 14 (2021).
Croasdell, A., Lacy, S. H., Thatcher, T. H., Sime, P. J. & Phipps, R. P. Resolvin D1 dampens pulmonary inflammation and promotes clearance of nontypeable Haemophilus influenzae. J. Immunol. 196, 2742–2752 (2016).
Abdulnour, R. E. et al. Aspirin-triggered resolvin D1 is produced during self-resolving gram-negative bacterial pneumonia and regulates host immune responses for the resolution of lung inflammation. Mucosal Immunol. 9, 1278–1287 (2016).
Norling, L. V. et al. Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis. JCI Insight 1, e85922 (2016).
Novosad, B. D., Astley, R. A. & Callegan, M. C. Role of Toll-like receptor (TLR) 2 in experimental Bacillus cereus endophthalmitis. PLoS ONE 6, e28619 (2011).
Ramadan, R. T., Ramirez, R., Novosad, B. D. & Callegan, M. C. Acute inflammation and loss of retinal architecture and function during experimental Bacillus endophthalmitis. Curr. Eye Res. 31, 955–965 (2006).
Lee, J. E., Sun, Y., Gjorstrup, P. & Pearlman, E. Inhibition of corneal inflammation by the resolvin E1. Invest Ophthalmol. Vis. Sci. 56, 2728–2736 (2015).
Krishnamoorthy, S., Recchiuti, A., Chiang, N., Fredman, G. & Serhan, C. N. Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am. J. Pathol. 180, 2018–2027 (2012).
Recchiuti, A., Krishnamoorthy, S., Fredman, G., Chiang, N. & Serhan, C. N. MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits. FASEB J. 25, 544–560 (2011).
Spite, M. et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461, 1287–1291 (2009).
Gordon, S. & Martinez, F. O. Alternative activation of macrophages: mechanism and functions. Immunity 32, 593–604 (2010).
Chiang, N. et al. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484, 524–528 (2012).
Norris, P. C. & Dennis, E. A. Omega-3 fatty acids cause dramatic changes in TLR4 and purinergic eicosanoid signaling. Proc. Natl. Acad. Sci. USA. 109, 8517–8522 (2012).
Koltsida, O. et al. Toll-like receptor 7 stimulates production of specialized pro-resolving lipid mediators and promotes resolution of airway inflammation. EMBO Mol. Med. 5, 762–775 (2013).
Corminboeuf, O. & Leroy, X. FPR2/ALXR agonists and the resolution of inflammation. J. Med. Chem. 58, 537–559 (2015).
Jannaway, M., Torrens, C., Warner, J. A. & Sampson, A. P. Resolvin E1, resolvin D1 and resolvin D2 inhibit constriction of rat thoracic aorta and human pulmonary artery induced by the thromboxane mimetic U46619. Br. J. Pharm. 175, 1100–1108 (2018).
Nelson, J. W. et al. ALX/FPR2 receptor for RvD1 is expressed and functional in salivary glands. Am. J. Physiol. Cell Physiol. 306, C178–C185 (2014).
Chen, K. et al. Activation of Toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid beta peptide. J. Biol. Chem. 281, 3651–3659 (2006).
Chen, K. et al. Cooperation between NOD2 and Toll-like receptor 2 ligands in the up-regulation of mouse mFPR2, a G-protein-coupled Abeta42 peptide receptor, in microglial cells. J. Leukoc. Biol. 83, 1467–1475 (2008).
Whiston, E. A. et al. alphaB-crystallin protects retinal tissue during Staphylococcus aureus-induced endophthalmitis. Infect. Immun. 76, 1781–1790 (2008).
Maddipati, K. R. et al. Eicosanomic profiling reveals dominance of the epoxygenase pathway in human amniotic fluid at term in spontaneous labor. FASEB J. 28, 4835–4846 (2014).
Maddipati, K. R. & Zhou, S. L. Stability and analysis of eicosanoids and docosanoids in tissue culture media. Prostaglandins Other Lipid Mediat. 94, 59–72 (2011).
Singh, P. K. et al. Zika virus infects cells lining the blood-retinal barrier and causes chorioretinal atrophy in mouse eyes. JCI Insight 2, e92340 (2017).